Analyst firms · H.C. Wainwright · GMAB
H.C. Wainwright GMAB price target and rating history
Genmab A/S (GMAB) · Health Care
H.C. Wainwright rates Genmab A/S (GMAB) Buy with a $47 price target, as of its latest action on Jan 31, 2022. It has published 3 rating actions on GMAB since August 2021, including 1 upgrade and 2 downgrades. Across 6 firms with a GMAB price target in the last 12 months, the median target is $40.
- Current rating
- Buy
- Price target
- $47
- Median target, all firms
- $40
- Actions on GMAB
- 3
H.C. Wainwright price target on GMAB
Every H.C. Wainwright rating on GMAB
- Jan 31, 2022
- Aug 24, 2021
- Aug 24, 2021
How other firms rate GMAB
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| TD Cowen | Buy | $43 | Jul 22, 2026 |
| Truist Securities | Buy | $40 | May 27, 2026 |
| Goldman Sachs | Buy | Apr 22, 2026 | |
| Wolfe Research | Outperform | $32 | Mar 27, 2026 |
| Wells Fargo | Overweight | $40 | Mar 2, 2026 |
| Jefferies | Buy | $41.50 | Feb 17, 2026 |
| Morgan Stanley | Equal-Weight | $34 | Feb 17, 2026 |
Questions about H.C. Wainwright and GMAB
- What is H.C. Wainwright's price target for GMAB?
- H.C. Wainwright's latest stated price target for Genmab A/S (GMAB) is $47, from its action on Jan 31, 2022.
- What is H.C. Wainwright's rating on GMAB?
- H.C. Wainwright rates GMAB Buy, a bullish rating, as of Jan 31, 2022.
- When did H.C. Wainwright last change its view on GMAB?
- On Jan 31, 2022, H.C. Wainwright upgrades to Buy from Neutral, price target $47.
- How does H.C. Wainwright's GMAB target compare with other analysts?
- Across 6 firms with a GMAB price target in the last 12 months, the median target is $40.
More GMAB rating histories
All H.C. Wainwright ratingsGMAB news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.